NYSEAMERICAN:OGEN - Oragenics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.74
▼ -0.04 (-5.13%)
1 month | 3 months | 12 months
Get New Oragenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oragenics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.74.

N/A

The current consensus among 0 investment analysts is to n/a stock in Oragenics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/2/2020HC WainwrightDowngradeHold
i
Rating by Ram Selvaraju at HC Wainwright
4/16/2020HC WainwrightDowngradeBuy ➝ Neutral
i
Rating by Y. Chen at HC Wainwright
3/31/2020HC WainwrightReiterated RatingBuy
i
Rating by Y. Chen at HC Wainwright
12/3/2019HC WainwrightReiterated RatingBuy$2.00
i
Rating by Yi Chen at HC Wainwright
11/21/2019HC WainwrightReiterated RatingBuy$2.00
i
Rating by Yi Chen at HC Wainwright
9/26/2019HC WainwrightReiterated RatingBuy$2.00
i
Rating by Yi Chen at HC Wainwright
8/16/2019HC WainwrightSet Price TargetBuy$2.00
i
Rating by Yi Chen at HC Wainwright
5/21/2019HC WainwrightReiterated RatingBuy$2.00
i
4/26/2019HC WainwrightReiterated RatingBuy
i
Rating by R. Selvaraju at HC Wainwright
4/26/2019HC WainwrightInitiated CoverageBuy$2.00
i
8/24/2016Griffin SecuritiesReiterated RatingBuy
i
Rating by K. Markey at Griffin Securities
(Data available from 6/16/2016 forward)
Oragenics logo
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Read More

Today's Range

Now: $0.74
$0.72
$0.79

50 Day Range

MA: $0.45
$0.42
$0.54

52 Week Range

Now: $0.74
$0.38
$2.09

Volume

1,801,806 shs

Average Volume

15,237,123 shs

Market Capitalization

$85.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Oragenics?

The following sell-side analysts have issued research reports on Oragenics in the last twelve months:
View the latest analyst ratings for OGEN.

What is the current price target for Oragenics?

0 Wall Street analysts have set twelve-month price targets for Oragenics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oragenics in the next year.
View the latest price targets for OGEN.

What is the current consensus analyst rating for Oragenics?

Oragenics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OGEN.

What other companies compete with Oragenics?

How do I contact Oragenics' investor relations team?

Oragenics' physical mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company's listed phone number is 813 286 7900 and its investor relations email address is [email protected] The official website for Oragenics is www.oragenics.com.